Nanolive label-free live cell
imaging and analysis
A revolution for cell biology
Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics
Nanolive delivers breakthrough label-free live cell imaging and analysis solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine screening, imaging and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.
Nanolive’s label-free live cell imaging and analysis platforms allow scientists to explore living cells in 3D without damaging them. By delivering complete measurements and understandings on a sub-cellular scale (e.g. mitochondrial networks, stem cell differentiation), Nanolive technology allows screening across thousands of live cell populations, and potential therapeutic use of those same, unperturbed, cells.
Application fields such as drug discovery, immuno-oncology, mitochondria & cell metabolism, neuroscience
Groundbreaking technology (platforms & consumables)
Swiss high precision and quality
Over 300 units installed worldwide
Award-winning technology
Patented product & technology
12’000 ft² headquarters in Switzerland with an international Team in USA & Europe
More than 1’000 citations in scientific papers
A deep understanding of live cells and their dynamics
Nanolive’s label-free live cell imaging and analysis platforms, consumables and services are built on technology that is 100% non-invasive, thus circumventing the use of current end-point assays that damage cells.
This allows live cells to be imaged and analyzed for an unlimited amount of time while characterizing their dynamics with the most reliable and quantitative results.
Our solutions are accelerating the drug discovery and development workflows of leading biopharma companies, transforming immuno-oncology, pathway discovery, mitochondrial & cell metabolism analysis, and sensitive cell line analytics. We are applying our technology to new research areas such as cell therapy manufacturing, regenerative medicine QA/QC and biotechnology.
Company history
2007-2012
Invention of Nanolive technology
2013
Company incorporation
Incorporation of Nanolive SA at EPFL Innovation Park, a spin-off from EPFL
2015
3D Cell Explorer
2017
3D Cell Explorer-fluo
2019
CX-A
2020
Business expansion
2022
Series C Financing Round
Closing of US $22.2 million in the series C equity financing round
Management Team
Yann Cotte, Ph.D.
Chief Executive Officer
Learn more
Dr. Cotte holds a Master in Physics from the State University of New York and a PhD in Holographic Microscopy from the École Polytechnique Fédérale de Lausanne (EPFL) in Lausanne. Dr. Cotte made a fundamental discovery in microscopy during his PhD and co-founded Nanolive in 2013 where he holds since foundation the position of CEO.
Mathieu Fréchin, Ph.D.
AI and Biology Director
Learn more
Dr. Mathieu Fréchin holds a PhD in Biophysics from the University of Strasbourg and continued his academic career at ETH/UNI Zurich in Systems Biology to study the role of cellular membranes. He joined Nanolive in June 2017, where he drives the development of innovative AI solution as the AI and Biology Director.
Lisa Pollaro, Ph.D.
Chief Marketing Officer
Learn more
Dr. Lisa Pollaro holds a Master in Pharmaceutical Biotechnology from Padua University and a PhD in Biochemical Engineering from the École Polytechnique Fédérale de Lausanne (EPFL) in Lausanne. Dr. Pollaro manages the marketing and communication team of Nanolive.
Award winning technology and products
